COVID-19

Researchers plan to monitor the immune responses of COVID-19 patients for one year to see how they correlate with illness severity and lasting effects. This data will help develop personalized treatments for patients.

How will your body respond to the vaccine?

Erica Ollman Saphire brings together scientific competitors to find new antibody therapeutics for COVID-19.

“Beyond COVID-19, we believe SMAs have huge potential to unblock constrictions in the drug pipeline.”

“The COVID-19 pandemic could be an opportunity for the companies pursuing the development of gene therapies, as few products are in development to fight the viral illness.”
Alessio Brunello of GlobalData

To be clear, any adverse event is always one too many. But in the real world, these things happen and often through no intrinsic fault of the therapeutic intervention

Genomenon and BC Platforms seek to combine their tech platforms to boost genomic research

Topline data from a recent Eli Lilly clinical trial indicate that tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide in adults with type 2 diabetes.

LIVE April 28th at 2:30 PM ET.
In this webinar, Adam Green will discuss vaccine separation and key considerations for optimizing filtration and membrane separation-based processes.